在治疗耐药双极性抑郁症中没有对胺的反应
Zofia Kachlik1, Wiesław Jerzy Cubała1, Michał Walaszek1
1Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland.
Neuropsychopharmacology reports
|August 29, 2025
概括
治疗耐药双极性抑郁症 (TRBD) 的胺酸不响应与更多的精神病并发症和先前使用二相关. 了解这些因素可以帮助优化胺抗抑郁药的治疗.
科学领域:
- 精神病学
- 药理学
背景情况:
- 胺是一种治疗耐药双极性抑郁症 (TRBD) 的快速作用抗抑郁药.
- 许多患者对胺治疗没有显著的反应.
- 这项研究研究了与TRBD患者的胺不反应相关的因素.
研究的目的:
- 在TRBD中探索区分胺不响应者和响应者的特征.
- 确定与治疗结果相关的基线特征.
主要方法:
- 一个自然主义研究的后期分析.
- 35 TRBD患者接受了为期四周的胺疗法 (IV或口服).
- 使用蒙哥马利- 阿斯伯格抑郁评分表评估反应;基线特征与反应者和非反应者进行比较.
主要成果:
- 40% 的患者 (14/35) 没有反应.
- 非响应者患有更多精神病并发症 (中位数为2对1) 和任何并发症的发病率更高 (78.6%对33.3%).
- 在不反应患者中,先前使用二的比例较高 (64. 3% vs 23. 8%).
结论:
- 在TRBD中,胺具有良好的短期安全性和耐受性.
- 较高的并发症负担和先前的二胺使用与胺无反应有关.
- 这些发现可以为TRBD提供个性化治疗策略.
相关概念视频
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Electroconvulsive Therapy
182
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
182
Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293
Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96


